Investing

Bank of America Corp.: “I think [CEO] Brian Moynihan is doing a remarkable job. It is one inexpensive stock. They keep buying back stock. It’s got a good yield. It’s going to get better because they’re going to raise the dividend. Buy, buy, buy.”

Pilgrim’s Pride Corp.: “I think it is a bit of a bottom-feeder there. Now, Tyson reports next week. I happen to like this one more than Tyson. It is a $5 billion company. I’ll go with you on that one. I’ll go with you.”

Kemet Corp.: “That’s an inexpensive capacitor stock. I’m going to go with you. It’s a very inexpensive stock, particularly after the cohort’s moved up.”

Moderna Inc.: “I pulled up with Moderna recently when I was out there at the J.P. Morgan [Healthcare] Conference, where we learned a ton of things, by the way. I’m sticking by that Bristol-Myers, and I think Moderna’s got a lot of game to it. It came public during a weird period in the IPO market. It’s clinical-stage biotech and I think it’s a great, but speculative situation.”

New Residential Investment Corp.: “I do not recommend these residential-market-related companies because I don’t really know what they own, and even though they could be very good companies, I’ve got to stick with what I do know and not recommend things that I don’t.”

The Boston Beer Co., Inc.: “Beer is flat. I can’t recommend anything in that category. May I tell you that Diageo is really good?”

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Products You May Like

Articles You May Like

Here’s how high health-care costs could get you a tax break on your 2018 return
A cat could be set to inherit a fortune after Karl Lagerfeld’s death
Fed expects to halt balance sheet reduction by the end of the year, minutes say
Walgreens and CVS are redesigning their drugstores to focus more on health. Here’s how they compare
Amazon leaves NYC: Good or Bad? With Anand Giridharadas and Robert Frank

Leave a Reply

Your email address will not be published. Required fields are marked *